Resmed Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Resmed is a widely held public company with a notable founder connection but no family control. Voting power follows economic ownership on a one-share one-vote basis, and the largest holders are the major index managers, Vanguard, BlackRock and State Street, reflecting the company membership in the leading benchmarks.The company was founded in 1989 by Peter Farrell, and his son Mick Farrell serves today as chairman and chief executive, providing continuity of leadership across the decades. Crucially, the Farrell family holds no dual-class or super-voting stock, so the company answers to its dispersed shareholders like any other widely held firm, with an independent board.For investors the ownership structure means strategy is judged by the market, tempered by the stability that founder-family leadership provides. Resmed dual listing on the New York and Australian exchanges broadens its holder base, and the absence of special voting rights keeps management fully accountable to that base for delivering growth and returns.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Resmed shareholder base is anchored by passive institutional capital, spread across its United States and Australian listings. Vanguard, BlackRock and State Street hold the largest positions, and the dual listing adds Australian institutional and retail holders to the register, broadening the base.Active investors own Resmed as a durable leader in sleep and respiratory care, drawn to its high-margin device and mask franchise and its recurring resupply revenue. In fiscal 2026 the company grew revenue 10 percent to 5.65 billion dollars with net income of 1.52 billion dollars and expanding margins, results that reflect strong demand and operational discipline that active holders value.Governance follows conventional norms with an independent board. Because no controlling owner exists, capital return through a rising dividend and share repurchases, totaling more than 1 billion dollars in fiscal 2026, is a primary lever to reward shareholders. The debate among owners has centered on the potential impact of weight-loss drugs on sleep apnea demand, a concern management argues is offset by a larger diagnosed patient population.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
Resmed competes through a portfolio of devices, masks and software concentrated in sleep and breathing health. Its AirSense line of continuous positive airway pressure devices is the flagship, and its AirFit masks and accessories generate high-margin recurring resupply revenue, together forming the core of a razor-and-blade model in sleep apnea therapy.Digital health is the strategic differentiator. The myAir patient app and a cloud-connected ecosystem spanning more than 140 countries support adherence and engagement, reinforcing Resmed leadership as sleep therapy becomes increasingly data-driven. This connected model deepens the company relationship with patients and providers.The software segment, historically built through Brightree and MatrixCare, extends Resmed into out-of-hospital care workflows, though the company agreed in 2026 to sell MatrixCare, sharpening its focus. The portfolio strategy centers on its dominant device and mask franchise, supported by digital health, while pruning software assets that fit less cleanly with the core.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Resmed is the leading maker of sleep apnea devices, operating in what is effectively a duopoly with Philips Respironics. With fiscal 2026 revenue of 5.65 billion dollars, it holds a commanding share of the continuous positive airway pressure market, a position strengthened after a major product recall sidelined Philips for an extended period.Its competitive edge is scale, a trusted device and mask franchise, and a connected digital health ecosystem that competitors have struggled to match. The recurring resupply of masks and consumables provides durable, high-margin revenue, while Resmed data platform reinforces switching costs for patients and providers.The most discussed risk is the potential effect of weight-loss drugs on the prevalence of sleep apnea, since obesity is a key driver of the condition. Resmed argues that these therapies expand awareness and the diagnosed population rather than shrinking demand, and its fiscal 2026 growth supported that view. Its competitive answer is continued device innovation, digital engagement and global expansion across 140 countries.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
Resmed has used acquisitions primarily to build a software and services layer on top of its core device business. The 2016 purchase of Brightree for roughly 800 million dollars began this strategy, adding software for home medical equipment providers, and the 2018 acquisition of MatrixCare extended it into long-term care.The company continued to expand this software footprint, notably with the 2022 acquisition of the German care-software provider MEDIFOX DAN for roughly 1 billion dollars, and more recently added remote patient monitoring through the 2025 purchase of VirtuOx. These deals aimed to position Resmed across the continuum of out-of-hospital care.The strategy has since been refined. In 2026 Resmed agreed to sell MatrixCare to a private equity buyer, signaling a decision to concentrate on its highest-value device, mask and connected-care franchises. The pattern reflects a company willing to both build and prune its software portfolio in service of focus.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Resmed structural history is one of organic growth punctuated by software acquisitions rather than transformational mergers. Founded in 1989 and public since 1995, the company built its core sleep and respiratory device franchise internally, establishing a dual listing on the New York and Australian exchanges that remains distinctive.The most significant structural moves have been in software. The acquisitions of Brightree in 2016, MatrixCare in 2018 and MEDIFOX DAN in 2022 built an out-of-hospital care software business alongside the devices, representing the company largest structural additions.The 2026 agreement to sell MatrixCare marks a partial reversal, trimming the software portfolio to refocus on core franchises. This willingness to both assemble and divest software assets reflects a company that treats structure as a tool for focus, avoiding the large mergers that reshaped some medical-device peers.
Ownership History
Ownership History Analysis
Resmed was founded in 1989 by Peter Farrell, who acquired the technology behind continuous positive airway pressure therapy and built a company to commercialize treatment for obstructive sleep apnea. The firm went public in 1995 and pioneered the market for sleep apnea devices, growing alongside rising awareness of the condition.Over the following decades Resmed expanded globally, innovated in quieter and smarter devices, and built a connected digital health ecosystem that turned a hardware business into a data-driven one. Leadership passed within the founding family to Mick Farrell, Peter Farrell son, who became chief executive in 2013 and later chairman.Today Resmed is the global leader in sleep and breathing health, led by Mick Farrell, with fiscal 2026 revenue of 5.65 billion dollars. Its history is one of building and dominating a new medical-device category, then extending it into digital health and connected care while remaining under founder-family leadership without family control.
Ownership Explained
Resmed is a widely held public company listed on the New York Stock Exchange and the Australian Securities Exchange with no controlling shareholder. Its largest owners are index managers, led by Vanguard, BlackRock and State Street. Mick Farrell serves as chairman and chief executive officer, the son of founder Peter Farrell, though the family holds no special voting control. The company was founded in 1989 and went public in 1995.
With dispersed ownership and one-share one-vote governance, Resmed answers fully to public shareholders and the capital markets. That accountability supports a strategy centered on its market-leading sleep and respiratory devices, a growing digital health ecosystem, and disciplined capital return. Management raised the dividend and returned more than 1 billion dollars to shareholders in fiscal 2026. The absence of family voting control leaves strategy subject to market discipline despite the founder connection at the top.